NASDAQ$BDTX
Black Diamond Therapeutics I · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Black Diamond Therapeutics reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Black Diamond Therapeutics reported a net loss of $18.2 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $115.2 million as of March 31, 2024, which is expected to fund operations into Q3 2025.
- Initiated dosing of patients with non-classical EGFR mutant NSCLC in the first-line setting for BDTX-1535.
- On track to release initial Phase 2 results from the ongoing second/third-line cohorts of BDTX-1535 in Q3 2024.
- Presented real-world evidence on the evolving EGFR mutation landscape at the 2024 AACR annual meeting.
- Cash, cash equivalents, and investments totaled $115.2 million as of March 31, 2024, expected to fund operations into Q3 2025.
Headline financials
Revenue & EPS history
Black Diamond Therapeutics · Revenue · Quarterly
$456K
Forward guidance
Black Diamond expects that its cash, cash equivalents and investments of $115.2 million will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the third quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-1.4%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-1.6%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+15.6%
Q4 2019
Best reaction
-19.6%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | +0.0% | -30.5% | |
| Q4 2025 | +2.4% | -3.7% | +33.3% | |
| Q3 2025 | -8.1% | -1.5% | -31.4% | |
| Q1 2025 | +2.1% | +5.2% | +19.7% | |
| Q4 2024 | -1.8% | +4.1% | -15.8% | |
| Q3 2024 | +10.0% | +10.0% | -21.4% | |
| Q2 2024 | -14.0% | -12.5% | +5.3% | |
| Q1 2024 | -12.0% | -17.3% | -25.2% | |
| Q4 2023 | +4.8% | +19.7% | +39.3% | |
| Q3 2023 | -4.2% | -6.3% | +24.7% | |
| Q2 2023 | -3.5% | -9.7% | +2.3% | |
| Q1 2023 | -2.1% | -1.6% | +11.5% | |
| Q4 2022 | -19.6% | +3.6% | -3.0% | |
| Q3 2022 | -2.7% | +13.6% | -28.1% | |
| Q2 2022 | +4.5% | +4.3% | -21.8% | |
| Q1 2022 | -9.4% | -8.4% | +5.4% | |
| Q4 2021 | +8.2% | +7.8% | +16.4% | |
| Q3 2021 | +2.0% | -4.0% | -22.8% | |
| Q2 2021 | -1.8% | -1.3% | +4.3% | |
| Q1 2021 | -4.0% | +9.0% | -50.3% | |
| Q4 2020 | +2.1% | +0.7% | +19.0% | |
| Q3 2020 | +9.2% | +3.2% | +8.1% | |
| Q2 2020 | -9.2% | -11.4% | -11.6% | |
| Q1 2020 | -1.1% | -5.4% | -19.5% | |
| Q4 2019 | +15.6% | +0.4% | +51.7% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro